Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 3/20 | 0.51 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.42 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.42 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13419179 | 0.98 | NOTUM (0.50) | NOTUMS1PR1ALDH1A1MAPTPDE3B | |
| SCHEMBL12017807 | 0.86 | ADRB2 (0.55) | ALDH1A1MAPTTHRBPDE3BPDE3A | |
| SCHEMBL13419438 | 0.86 | HTR6 (0.51) | NOTUM | |
| SCHEMBL15759210 | 0.85 | L3MBTL3 (0.45) | NOTUMALDH1A1GAA | |
| SCHEMBL12017704 | 0.85 | ADRB2 (0.56) | — | |
| SCHEMBL7911412 | 0.85 | NOTUM (0.54) | NOTUMS1PR1ALDH1A1MAPTTHRB | |
| SCHEMBL16729408 | 0.84 | NOTUM (0.50) | NOTUMS1PR1ALDH1A1MAPTMEN1 | |
| SCHEMBL13419429 | 0.82 | SSTR2 (0.40) | NOTUMALDH1A1MAPTMEN1GAA | |
| SCHEMBL15726858 | 0.82 | ALDH1A1 (0.45) | ALDH1A1MAPTMEN1GAATHRB | |
| SCHEMBL20374410 | 0.81 | HSD11B1 (0.43) | NOTUMPDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022268154-A1 | NEW ANTI-HEPATITIS B COMPOUND | 上海齐鲁制药研究中心有限公司 | 2022-12-29 | — | — | WO | disclosed |
| US-20130243754-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | TARGEGEN, INC. (US) | 2013-09-19 | — | — | US | disclosed |
| US-8372971-B2 | Heterocyclic compounds and methods of use | TARGEGEN, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-20120220584-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | TARGEGEN, INC. (US) | 2012-08-30 | — | — | US | disclosed |
| US-7652051-B2 | Heterocyclic compounds and methods of use | TARGEGEN, INC. (US) | 2010-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220584-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AADAC, NISCH, PAICS | NOTUM 2113/4885S1PR1 4656/4885ALDH1A1 1642/4885 |
| US-20130243754-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AADAC, NISCH, PAICS | NOTUM 2113/4885S1PR1 4656/4885ALDH1A1 1642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.